Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Letters

Recommendations for stroke: 2010

Alexandre Ackaoui and Jean-Pierre Pellerin
CMAJ October 04, 2011 183 (14) 1627-1629; DOI: https://doi.org/10.1503/cmaj.111-2075
Alexandre Ackaoui
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Pierre Pellerin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

The inclusion of dabigatran in the 2010 Canadian guidelines for stroke care,1 and more recently in the updated practice guidelines from the American College of Cardiology Foundation, American Heart Association and Heart Rhythm Association,2 is important because of the need for an alternative to warfarin for anticoagulation in patients with atrial afibrillation.

In his interesting commentary in CMAJ, Rudd emphasizes that dabigatran is recommended for patients meeting the inclusion criteria of the RE-LY (Randomized Evaluation of Long term anticoagulant therapY) trial.3 Rudd notices that this recommendation is made “despite a lack of data on the long-term safety and efficacy of this drug.” The guidelines appear to support the use of dabigatran as an alternative to warfarin without any restrictions. However, we expected a more critical update from the guideline developers on the RE-LY study that would have included some reservations about the use of this molecule.

First, Connolly and colleagues analyze their data under the intention-to-treat principle.4,5 In this specific case, because the analysis does not take into account the number of dropouts in the patient groups, it overestimates the effects of dabigatran by 4% to 11% for embolic or hemorrhagic cerebrovascular or transient ischemic attack. This observation is important given that dropout rates are higher in the groups receiving dabigatran (21%) than in those receiving warfarin (16%). On the contrary, analysis based on the number of patients who completed the study shows some modification of these results: the result for non-specific ischemia, dabigatran 150 mg v. warfarin, becomes nonsignificant (rate ratio [RR] 0.82, 95% confidence interval [CI] 0.64–1.05); the result for myocardial infarction becomes significant in favour of warfarin in comparisons of dabigatran 110 mg v. warfarin (RR 1.44, 95% CI 1.04–1.99) and dabigatran 150 mg v. warfarin (RR 1.49, 95% CI 1.07–2.49); and the result for hospital admissions becomes nonsignificant when comparing dabigatran 110 mg v. warfarin (RR 0.99, 95% CI 0.95–1.03).

Second, the RE-LY study shows that dabigatran requires an acid environment for absorption; hence, the addition of an acidifying agent is required to allow absorption, and this is what seems to cause dyspepsia and eventually hemorrhage with that molecule. Yet Connolly and colleagues present the results in patients with and without a proton pump inhibitor (PPI).5 Analysis of these results shows a marked reduction in the effectiveness of dabigatran 150 mg when taken with a PPI (RR 0.94, 95% CI 0.56–1.58). This is a predictable result, given the mechanism of action of PPIs. Thus, a warning should be issued about the use of dabigatran in patients taking a PPI until there are controlled studies that show its effectiveness under this condition. The use of PPIs and any antacids to prevent dyspepsia secondary to dabigatran should also be discouraged.

Out of concern for scientific rigour and to protect patients, we believe a warning about the use of dabigatran should be included in the recommendations to be issued in the Canadian practice guidelines on the possibility of substituting this new oral coagulant for warfarin.

References

  1. ↵
    1. Lindsay MP,
    2. Gubitz G,
    3. Bayley M,
    4. et al
    . Canadian best practice recommendations for stroke care (update 2010). Ottawa (ON): Canadian Stroke Network; 2010.
  2. ↵
    1. Wann LS,
    2. Curtis AB,
    3. Ellenbogen KA,
    4. et al
    . 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011;123:1144–50.
    OpenUrlFREE Full Text
  3. ↵
    1. Rudd AG
    . Recommendations for stroke in 2010: a challenging agenda. CMAJ 2011;183:E171–2.
    OpenUrlFREE Full Text
  4. ↵
    1. Connolly SJ,
    2. Ezekowitz MD,
    3. Yusuf S,
    4. et al
    . Newly identified events in the RE-LY trial. N Engl J Med 2010;363:1875–6.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Connolly SJ,
    2. Ezekowitz MD,
    3. Yusuf S,
    4. et al
    . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–51.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 183 (14)
CMAJ
Vol. 183, Issue 14
4 Oct 2011
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Recommendations for stroke: 2010
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Recommendations for stroke: 2010
Alexandre Ackaoui, Jean-Pierre Pellerin
CMAJ Oct 2011, 183 (14) 1627-1629; DOI: 10.1503/cmaj.111-2075

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Recommendations for stroke: 2010
Alexandre Ackaoui, Jean-Pierre Pellerin
CMAJ Oct 2011, 183 (14) 1627-1629; DOI: 10.1503/cmaj.111-2075
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Succinylcholine, malignant hyperthermia and rhabdomyolysis
  • The authors respond to criticisms of their model parameters
  • Error in key model input
Show more Letters

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire